Nafamostat mesylate
Nafamostat mesylate is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target complement C1r subcomponent, trypsin-1, acid-sensing ion channel 1, acid-sensing ion channel 2, acid-sensing ion channel 3, transient receptor potential cation channel subfamily M member 7, and tryptase alpha/beta-1.
| Trade Name | |
|---|---|
| Common Name | Nafamostat mesylate |
| Indication | |
| Drug Class | Enzyme inhibitors: proteolytic enzyme inhibitors |
